Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

View Full Paper
Ask AI
Bookmark
Share

Authors

FFFrancesc Fernández-AvilésCLCarlos Fernández de LarreaNTNatalia Tovar

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals improved progression free survival in multiple myeloma after novel agents induction therapy, indicating higher long-term success rates.

Key Points

  • Operational cure achieved in 12% of newly diagnosed multiple myeloma patients after autologous stem cell transplantation.
  • Progression free survival was 48.2 months for those who achieved complete response post-transplantation, compared to 25.2 months for others.
  • Survival analysis indicated significant differences in overall survival for patients treated with novel agents versus chemotherapy-based induction.
  • Incorporation of novel agents like lenalidomide may enhance long-term treatment outcomes in multiple myeloma.

Cite This Study

Fernández-Avilés et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e176https://doi.org/10.1182/blood-2025-5776
View Full Paper
Ask AI
Bookmark
Share